FibroGen, Inc (FGEN) Q3 2025 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Kyntra Bio, Inc..

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.031 -- 00:00:05.398 Hello, and thank you for standing by. Welcome to FiberGen Third Quarter 2025 00:00:05.398 -- 00:00:10.864 Earnings Conference Call. At this time, all participants are on a listen-only mode. 00:00:10.864 -- 00:00:15.150 After the speaker's presentation, there will be a question and answer session. 00:00:15.150 -- 00:00:19.976 To ask a question during the session, you will need to press Start 11 on your telephone. 00:00:19.976 -- 00:00:23.700 You will then hear an automated message advising your hand is raised. 00:00:23.700 -- 00:00:27.505 To withdraw your question, please press Start 11 again. 00:00:27.505 -- 00:00:29.967 I would now like to hand the conference over to Gaia Seamus. 00:00:29.967 -- 00:00:32.270 You may begin. 00:00:32.270 -- 00:00:37.117 Thank you, Amanda. Good afternoon, everyone, and thank you for joining us today to discuss 00:00:37.117 -- 00:00:40.662 FibroGen's third quarter 2025 financial 00:00:40.662 -- 00:00:45.008 and business results. I'm Gaia Chamis from Lysa Advisors. 00:00:45.008 -- 00:00:50.055 Joining me on today's call are Thayne Wettig, Chief Executive Officer, and David 00:00:50.055 -- 00:00:55.091 DeLucia, Chief Financial Officer. Following the prepared remarks, we will open the call 00:00:55.091 -- 00:01:00.278 to your questions. I would like to remind you that remarks made on today's call include 00:01:00.278 -- 00:01:03.302 forward-looking statements about FibroGen. 00:01:03.302 -- 00:01:08.328 Such statements may include, but are not limited to, collaboration with AstraZeneca and 00:01:08.328 -- 00:01:13.595 Astellas, financial guidance, the initiation, enrollment, design, conduct, 00:01:13.595 -- 00:01:18.741 and results of clinical trials, regulatory strategies, and potential regulatory 00:01...